Bark (NYSE:BARK) Misses Q1 CY2026 Sales Expectations
Bark (NYSE: BARK) reported Q1 CY2026 sales of $86.57M, below analyst estimates of $95.2M, a 25% year-on-year decline. Adjusted EPS was $0.07 versus -$0.40 expected, and adjusted EBITDA was $3.17M versus $814K expected. Q2 CY2026 revenue guidance is $78M (midpoint), below $105M estimates; FY2027 EBITDA guidance is $8.5M (midpoint).
Revenue miss plus below-consensus Q2 guidance, despite adjusted EPS/EBITDA beats, shifts focus to demand/trajectory risk.
Bark missed Q1 CY2026 sales expectations ($86.57M vs $95.2M) and guided Q2 revenue to $78M vs $105M estimates.
Likely downside bias as guidance shortfall can outweigh margin/EPS beats; watch for follow-through selling into next session.
Background
The piece reports Bark’s Q1 CY2026 results versus analyst estimates and provides Q2 CY2026 and FY2027 guidance.
Why it matters
Traders will likely reprice Bark on the combination of a revenue miss, below-consensus Q2 revenue guidance, and weaker operating profitability/FCF, even though adjusted EPS and EBITDA beat expectations.
Market relevance
A guidance-driven setup: Q2 revenue midpoint ($78M) is well below consensus ($105M), increasing downside risk despite adjusted profitability beats.
Market effects
Signals potential softness in the company’s demand environment, which can pressure sentiment for similarly positioned consumer/animal-related growth names.
Primarily single-name risk; limited direct regional spillover implied by the text.
No global macro or cross-border drivers mentioned beyond company-specific guidance.
Alternative perspectives
Adjusted EPS and EBITDA beats suggest cost discipline; if investors believe the revenue miss is temporary, the stock could stabilize after the initial guidance shock.
The article highlights free cash flow deterioration and worsening operating margin, which may indicate structural issues beyond near-term sales timing.
Key entities
- companyBark
Reports Q1 CY2026 sales miss and issues Q2 CY2026 revenue guidance below consensus; also provides FY2027 EBITDA guidance above consensus.

